NCT06640972View on ClinicalTrials.gov

Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

September 27, 2024

Primary Completion Date

January 4, 2025

Study Completion Date

April 30, 2025

Conditions
TriglyceridesWeight Gain TrajectoryCholesterol, Elevated
Interventions
DRUG

RDX-002

Gut-specific microsomal triglyceride transfer protein (MTP) inhibitor

DRUG

Placebo

Matching placebo

Trial Locations (1)

55114

Nucleus Network, Saint Paul

Sponsors
All Listed Sponsors
lead

Response Pharmaceuticals

INDUSTRY

NCT06640972 - Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists | Biotech Hunter | Biotech Hunter